Atrial and Brain Natriuretic Peptide Secretion After Percutaneous Closure of the Left Atrial Appendage

Not Applicable

• Conditions: Atrial Fibrillation; Stroke Prevention; Left Atrial Appendage
• Interventions: Device: WATCHMAN LAA system (Percutaneous left atrial appendage closure)

• Registration Number: NCT01522911
• Lead Sponsor: University of Leipzig

Brief Summary

To date there are no data suggesting substantial effects of hormonal interaction after percutaneous closure of the left atrial appendage (LAA). Our hypothesis is that by excluding the LAA from blood flow physiologic stimuli for ANP and BNP produce may be impaired and consecutive release of the hormones may be reduced. Here, we present our experience of ANP and BNP secretion in the early postprocedural period after transcatheter closure of the LAA.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-05
• Study First Submitted: 2011-12-20
• Status Verified: 2012-01
• Primary Completion: 2012-01
• Study Completion: 2012-01
• Study First Submitted QC: 2012-01-30
• Last Update Submitted: 2012-01-30
• Study First Posted: 2012-02-01
• Last Update Posted: 2012-02-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• non-valvular atrial fibrillation
• increased risk for thromboembolic complications (a minimum CHADS2Score of at least 2)

Exclusion Criteria

• Valvular-atrial fibrillation
• Low risk for thromboembolic complications CHADS-2-Score < 2

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
atrial and brain natriuretic peptide	WATCHMAN LAA system (Percutaneous left atrial appendage closure)	Impact on atrial an brain natriuretic peptide secretion after percutaneous left atrial appendage closure

Primary Outcome Measures

Name	Time	Method
Change from Baseline Plasma ANP and BNP levels after transcatheter closure of the left atrial appendage.	participants will be followed for the duration of hospital stay, an expected average of 48 hours	Venous blood samples are taken before the procedure, immediately after implantation of the LAA closure device and on the first morning after the procedure. The blood is drawn into plastic tubes containing aprotinin and ethylenediaminetetraacetic acid disodium and is promptly centrifuged. The plasma obtained is stored at -20°C until assayed. The plasma BNP and ANP concentrations are then determined with a commercially available enzyme immunoassay kit (ELISA Kit for Brain Natriuretic Peptide, Uscn Life Science Inc., Missouri City, USA and ANP ELISA Kit, Hölzel Diagnostika, Köln, Germany).